despite treatment with the first TNFi used, we strongly recommend against switching to treatment with a biosimilar of the first TNFi (new, PICO 62). In adults with active AS despite treatment with the first TNFi used, we conditionally recommend against the addition of sulfasalazine or methotrexate in favor of switching to a new biologic (PICO 9). Direct comparisons of treatment strategies for patients who do not have or sustain adequate responses to their first TNFi have not been reported, and